The impact of the COVID-19 pandemic on prescription drug use in patients with Psoriasis Vulgaris in Germany

The findings reveal that despite the challenges of COVID-19, sales of first-line biologics and second-line psoriasis treatments increased across Germany—except in regions with very high infection rates. Discover how real-world evidence from prescription data can inform resilient treatment strategies during public health crises.

By Kahn, M., Papukchieva, S., Jacyshyn-Owen, E., Grimm, S., Eberl, M., Schneeweiss, S., Otten, M., Augustin, M. & Friedrich, B. (2023) The Impact of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany. Springer Link,  Dermatology and Therapy Volume 13, pages 2609–2620, (2023)